Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer
Pfizer’s oral cyclin-dependent kinase 4 (CDK4) inhibitor, atirmociclib, has met the primary endpoint in a Phase II trial as a…
Oncology
-
-
Roche’s oral SERD fails in Phase III breast cancer trial
Roche’s oral selective oestrogen receptor degrader (SERD) has failed to meet its primary endpoint in a Phase III breast cancer…
-
Second Pfizer Braftovi regimen shows benefit in mCRC
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF…
-
Lilly’s Retevmo boosts event-free survival in early-stage NSCLC
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in…
-
WHO analysis shows four in ten cancers could be prevented
Globally, cancer is a leading cause of death and presents a significant challenge to public health. Despite major therapeutic advances…
-
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
-
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a…
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15…
-
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell…
-
JPM26: Roche’s rejuvenation strategy for the oncology and haematology portfolio
At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few…
